Related content

Patient-derived xenografts reveal limits to PI3K/mTOR- and MEK-mediated inhibition of bladder cancer

By Cirone Pasquale   Andresen Catharine   Eswaraka Jeetendra   Lappin Patrick   Bagi Cedo  

Cancer Chemotherapy and Pharmacology, Vol. 73, Iss. 3, 2014-03 ,pp. : 525-538

Springer Publishing Company

Access to resources Recommend Favorite

Increased activation of PI3K/AKT signaling pathway is associated with cholangiocarcinoma metastasis and PI3K/mTOR inhibition presents a possible therapeutic strategy

By Yothaisong Supak   Dokduang Hasaya   Techasen Anchalee   Namwat Nisana   Yongvanit Puangrat   Bhudhisawasdi Vajarabhongsa   Puapairoj Anucha   Riggins Gregory   Loilome Watcharin  

Tumor Biology, Vol. 34, Iss. 6, 2013-12 ,pp. : 3637-3648

Springer Publishing Company

Access to resources Recommend Favorite

Potential Molecular Targeted Therapeutics: Role of PI3-K/Akt/mTOR Inhibition in Cancer

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 16, Iss. 1, 2016-01 ,pp. : 29-37

Bentham Science Publishers

Access to resources Recommend Favorite

Editorial (Hot Topic: Inhibition of PI3K/Akt/mTOR Signaling by Natural Products)

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 13, Iss. 7, 2013-09 ,pp. : 967-970

Bentham Science Publishers

Access to resources Recommend Favorite

NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells

By                    

International Journal of Oncology, Vol. 45, Iss. 3, 2014-01 ,pp. : 1027-1035

Spandidos Publications

Access to resources Recommend Favorite